How Pfizer’s and Moderna’s mRNA-based COVID-19 vaccines work

The COVID-19 pandemic has driven a massive allocation of resources toward producing solutions, from identifying life-saving medications, tracking how the virus spreads and ultimately to preventing infection with vaccines.

As a physician scientist, I study how the virus has evolved over the pandemic, since any changes in the virus could also change the effectiveness of current treatments. On Nov. 9, Pfizer announced preliminary trial results showing that a vaccine it developed with BioNTech was about 90 per cent effective. That was followed up nine days later with final trial results and two months of safety data, indicating a 95 per cent effectiveness rate.

READ MORE: Pfizer applies for emergency coronavirus vaccine approval in U.S.

Pfizer announced on Nov. 18 that it intends to file for emergency authorization with the U.S. Food and Drug Administration.

Meanwhile, on Nov. 16, Moderna announced preliminary results for its own vaccine, developed with the U.S. National Institutes of Health, which also indicated effectiveness of about 95 per cent.

This is good news, but we need to understand what it means so life can ultimately go back to normal.

1:21 Coronavirus: Dr. Fauci urges people to abide by measures, avoid COVID-19 fatigue as ‘help is on the way’

DNA, messenger RNA and proteins

Both Pfizer’s and Moderna’s vaccines are mRNA-based. In each of our cells, DNA produces messenger RNA (mRNA) containing the templates for making proteins. It’s called messenger RNA because it carries that information to other parts of the cell, where the instructions are read and followed to produce specific proteins.

When a patient is injected with mRNA in a vaccine, their cells use the information in that mRNA to create a protein: in this case, a version of the spike protein from the coronavirus that causes COVID-19. The immune system recognizes that protein as a signal to produce antibodies and immune cells.

An mRNA vaccine has some advantages for mass vaccination. It can produce robust immunity, can be made rapidly at low cost, and, like inactivated and subunit vaccines, it is impossible for it to cause someone to develop the illness.

Building immunity

This vaccine has the potential to protect many people from this devastating virus. When it is said that a vaccine is 90 per cent effective, this means that if 100 people received the vaccine and were then exposed to the virus, 90 would be unlikely to get sick. While 10 would be at risk of still developing the infection, protection from vaccines is not all-or-nothing. These 10 individuals could have milder disease than someone who did not receive the vaccine.

1:08 Coronavirus: Pfizer applied for Health Canada approval of its vaccine, pending “rolling review” process

It takes time for immune systems to prepare to fight infections. Think of building immunity to SARS-CoV-2, the virus that causes COVID-19, as like preparing to run a marathon. First, the runner must register, just as the immune system must be exposed to the infectious agent. Then, they need to build stamina. For the immune system, this means making antibodies and immune cells. Finally, they run the marathon: the bolstered immune system now removes the infectious agent from the body, or prevents it from doing further damage.

In both the Pfizer and Moderna clinical trials, subjects received the vaccine in two doses, three or four weeks apart, respectively. That’s about how much time it takes for the stimulated immune system to produce meaningful protection. A booster vaccine was given to produce even more antibodies and immune cells. In terms of the marathon example, this is like doing a practice marathon around three weeks into training. The runner will do better than they would have on day one, but more training is likely still needed. The booster vaccine provides that extra training.

The beginning of the end

Should we expect the pandemic to be over once a vaccine is available for public use? Not exactly. A vaccine will not be perfect, and it takes time for the immune system to be ready to protect us.

In addition, it is possible that the vaccines will be less effective than cited. Clinical trials are carefully set up, but it is possible that the virus will have evolved enough since the vaccines were designed so they will provide less benefit. It will also take time for enough vaccine to be made and administered for the population to achieve herd immunity.

Masks and social distancing will still most likely be necessary throughout 2021 because it takes time to accomplish such large-scale projects. We cannot expect herd immunity from our neighbours getting sick to get the world back to normal, even while neighbours are receiving vaccines. The human cost is unacceptable and the virus is too infectious for this to produce meaningful results unless 67 per cent of the population is infected, with a lot of people dying up to that point and afterwards.

Julian Daniel Sunday Willett, PhD Student, quantitative life sciences, McGill University

This article is republished from The Conversation under a Creative Commons licence. Read the original article.